What is Lifesci Capital's Estimate for COGT Q2 Earnings?

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2025 earnings estimates for shares of Cogent Biosciences in a report issued on Monday, June 30th. Lifesci Capital analyst S. Slutsky anticipates that the technology company will post earnings per share of ($0.63) for the quarter. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Lifesci Capital also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.21) EPS.

Several other research analysts also recently commented on COGT. Piper Sandler raised shares of Cogent Biosciences to a "strong-buy" rating in a report on Friday, March 7th. Robert W. Baird dropped their price objective on Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a research note on Tuesday, June 17th. JPMorgan Chase & Co. raised their price target on Cogent Biosciences from $21.00 to $25.00 and gave the company an "overweight" rating in a report on Thursday, May 29th. Finally, Scotiabank initiated coverage on Cogent Biosciences in a report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 price objective for the company. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.43.

Cogent Biosciences Trading Up 2.6%

Shares of COGT stock traded up $0.19 during trading hours on Tuesday, reaching $7.41. The stock had a trading volume of 1,778,449 shares, compared to its average volume of 1,340,967. The stock's fifty day simple moving average is $5.86 and its 200 day simple moving average is $6.75. The firm has a market capitalization of $843.70 million, a PE ratio of -4.03 and a beta of 1.88. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.04.

Hedge Funds Weigh In On Cogent Biosciences

A number of large investors have recently added to or reduced their stakes in COGT. Strs Ohio bought a new position in shares of Cogent Biosciences during the first quarter valued at about $36,000. CWM LLC increased its stake in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock worth $52,000 after purchasing an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Cogent Biosciences in the fourth quarter valued at approximately $78,000. Hsbc Holdings PLC bought a new stake in Cogent Biosciences in the fourth quarter valued at approximately $81,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Cogent Biosciences during the fourth quarter valued at approximately $88,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.